C4 Therapeutics (CCCC)
NASDAQ:CCCC
Want to see CCCC full AI Analyst Report?
CCCC Stock Chart & Stats
$2.92
-$0.05(-1.30%)
At close: 4:00 PM EST
$2.92
-$0.05(-1.30%)
Day’s Range― - ―
52-Week Range$1.21 - $3.82
Previous CloseN/A
Volume165.25K
Average Volume (3M)2.88M
Market Cap
$289.81M
Enterprise Value$223.92M
Total Cash (Recent Filing)$248.54M
Total Debt (Recent Filing)$59.98M
Price to Earnings (P/E)―
Beta2.21
Next Earnings
May 13, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding97,578,180
10 Day Avg. Volume4,147,757
30 Day Avg. Volume2,878,552
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.62
Price to Sales (P/S)4.40
P/FCF Ratio-1.59
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue6.23
Enterprise Value/Gross Profit6.56
Enterprise Value/Ebitda-2.07
Forecast
1Y Price Target
$14.50Price Target Upside396.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$21.62M
Bulls Say, Bears Say
Bulls Say
Expanded Roche CollaborationA deeper, decade-long Roche partnership materially strengthens non-dilutive funding and validates C4T's degrader expertise. Roche leading development and commercialization shifts late-stage costs off C4, while tiered milestones/royalties create a durable upside stream tied to partner-led product success.
TORPEDO Platform And Partnership ModelA platform-centric R&D model builds transferable IP and scale: designing degrader payloads for partners lets C4 capture upfront fees, research funding, milestones and royalties without bearing full commercialization cost, creating a durable competitive position in the emerging degrader modality.
Moderate Leverage And Meaningful Equity BaseA sizeable equity buffer and low relative debt provide financial flexibility to fund clinical programs or negotiate deals without immediate insolvency risk. Moderate leverage lengthens runway and enhances optionality for partnering or staged financing while development milestones are pursued.
Bears Say
Persistent Negative Cash FlowSustained, large negative operating and free cash flow materially increases financing needs and dilution risk. Without a shift to positive cash generation or secured milestone funding, management must rely on partner payments or capital markets, constraining long-term strategic options.
Revenue Collapse And VolatilityA drop to zero reported revenue eliminates recurring commercial inflows and undermines predictability. This structural revenue weakness heightens reliance on partnerships and milestones, making sustainable funding and long-term planning contingent on successful, binary development outcomes.
Reliance On Milestone/licensing TimingDependence on partner-triggered milestones and royalties creates lumpy, outcome-dependent cash flows. Structural timing uncertainty around clinical and regulatory milestones increases funding risk and makes consistent revenue generation unlikely until partnered assets reach commercialization.
C4 Therapeutics News
CCCC FAQ
What was C4 Therapeutics’s price range in the past 12 months?
C4 Therapeutics lowest stock price was $1.21 and its highest was $3.82 in the past 12 months.
What is C4 Therapeutics’s market cap?
C4 Therapeutics’s market cap is $289.81M.
When is C4 Therapeutics’s upcoming earnings report date?
C4 Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 18 days.
How were C4 Therapeutics’s earnings last quarter?
C4 Therapeutics released its earnings results on Feb 26, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.288 by $0.108.
Is C4 Therapeutics overvalued?
According to Wall Street analysts C4 Therapeutics’s price is currently Undervalued.
Does C4 Therapeutics pay dividends?
C4 Therapeutics does not currently pay dividends.
What is C4 Therapeutics’s EPS estimate?
C4 Therapeutics’s EPS estimate is -0.25.
How many shares outstanding does C4 Therapeutics have?
C4 Therapeutics has 97,578,180 shares outstanding.
What happened to C4 Therapeutics’s price movement after its last earnings report?
C4 Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.288. Following the earnings report the stock price went up 0.361%.
Which hedge fund is a major shareholder of C4 Therapeutics?
Currently, no hedge funds are holding shares in CCCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
C4 Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (396.58% Upside)
$14.50 (396.58% Upside)
Blogger Sentiment
Bullish
CCCC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 8.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.5%
Last 30 Days ▲ 18.8%
Last 30 Days ▲ 18.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
133.60%
12-Months-Change
Fundamentals
Return on Equity
-53.83%
Trailing 12-Months
Asset Growth
6.39%
Trailing 12-Months
Company Description
C4 Therapeutics
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
CCCC Stock 12 Month Forecast
Average Price Target
$14.50
▲(396.58% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Seres Therapeutics
―
Eledon Pharmaceuticals
―
Tevogen Bio Holdings
―
Actuate Therapeutics, Inc.
―
Ownership Overview
3.36% Insiders
9.75% Mutual Funds
0.87% Other Institutional Investors
79.76% Public Companies and
Individual Investors